Development of a Recombinant Pichinde Virus-Vectored Vaccine against Turkey Arthritis Reovirus and Its Immunological Response Characterization in Vaccinated Animals
| Autor: | Hinh Ly, Robert E. Porter, Sunil K. Mor, Tamer A. Sharafeldin, Yuying Liang, Rahul Kumar, Sagar M. Goyal, Pawan Kumar, Qinfeng Huang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
lcsh:Medicine Biology Article law.invention recombinant vaccine Antigen sigma B law sigma C Immunology and Allergy viral vectored vaccine Pichinde virus Molecular Biology Polymerase chain reaction General Immunology and Microbiology Immunogenicity lcsh:R Antibody titer Virology Reverse transcriptase Reverse genetics Vaccination Infectious Diseases Recombinant DNA turkey arthritis reovirus subunit vaccine |
| Zdroj: | Pathogens, Vol 10, Iss 197, p 197 (2021) Pathogens Volume 10 Issue 2 |
| ISSN: | 2076-0817 |
| DOI: | 10.3390/pathogens10020197 |
| Popis: | Vaccination may be an effective way to reduce turkey arthritis reovirus (TARV)-induced lameness in turkey flocks. However, there are currently no commercial vaccines available against TARV infection. Here, we describe the use of reverse genetics technology to generate a recombinant Pichinde virus (PICV) that expresses the Sigma C and/or Sigma B proteins of TARV as antigens. Nine recombinant PICV-based TARV vaccines were developed carrying the wild-type S1 (Sigma C) and/or S3 (Sigma B) genes from three different TARV strains. In addition, three recombinant PICV-based TARV vaccines were produced carrying codon-optimized S1 and/or S3 genes of a TARV strain. The S1 and S3 genes and antigens were found to be expressed in virus-infected cells via reverse transcriptase polymerase chain reaction (RT-PCR) and the direct fluorescent antibody (DFA) technique, respectively. Turkey poults inoculated with the recombinant PICV-based TARV vaccine expressing the bivalent TARV S1 and S3 antigens developed high anti-TARV antibody titers, indicating the immunogenicity (and safety) of this vaccine. Future in vivo challenge studies using a turkey reovirus infection model will determine the optimum dose and protective efficacy of this recombinant virus-vectored candidate vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|